NCT01990469View on ClinicalTrials.gov

Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin

PHASE3CompletedINTERVENTIONAL

Enrollment

219

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

T2DM

Interventions

DRUG

Gemigliptin

DPP-4 inhibitor

DRUG

Gemigliptin placebo

Placebo of Gemigliptin

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY

NCT01990469 - Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin | Biotech Hunter | Biotech Hunter